CoChat

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Rationale: IL-13 is a potential therapeutic target for idiopathic pulmonary fibrosis (IPF); preclinical data suggest a role in tissue fibrosis, and expression is increased in subjects with rapidly progressing disease. Objectives: Investigate efficacy and safety of tralokinumab, a human anti–IL-13 monoclonal antibody, in subjects with mild to moderate IPF. Methods: Subjects received tralokinumab (400 or 800 mg), or placebo, intravenously every 4 weeks for 68 weeks. The primary endpoint was change from baseline to Week 52 in percent predicted FVC in the intention-to-treat population. Exploratory analyses included assessment of clinical response in subgroups with baseline serum periostin concentration above/below median. Measurements and Main Results: The study was stopped due to lack of efficacy after interim analysis. Neither tralokinumab 400 mg nor tralokinumab 800 mg met the primary endpoint; least-squares mean difference (95% confidence interval) percent predicted FVC from baseline to Week 52: −1.77 (−4.13 to 0.59) (P = 0.140) and −1.41 (−3.73 to 0.91) (P = 0.234), respectively. The primary endpoint was also not met in either treatment group in subgroups defined by periostin baseline concentration. The percentage of subjects with decline in percent predicted FVC greater than or equal to 10% at Week 52 was numerically greater for tralokinumab-treated subjects compared with placebo. The most common treatment-emergent adverse events for tralokinumab 400 mg, tralokinumab 800 mg, and placebo were cough (17.5, 30.5, 22.8%), IPF progression and exacerbation (21.1, 16.9, 22.8%), and upper respiratory tract infection (17.5, 20.3, 12.3%), respectively. Conclusions: Tralokinumab demonstrated an acceptable safety and tolerability profile but did not achieve key efficacy endpoints. Clinical trial registered with www.clinicaltrials.gov (NCT01629667).

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.201704-0784oc

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 23 · Cited by 129

Research works printed but not linked: 2

  1. Glassberg, 2017, Effect of pirfenidone on breathlessness as measured by the UCSD-SOBQ score in patients with idiopathic pulmonary fibrosis (IPF) with moderate lung function impairment [abstract], Am J Respir Crit Care Med, 195, A5406
  2. Duguid, 2015, IL-13 is a driver of pulmonary fibrosis in the Fra-2 transgenic mouse model [abstract], Am J Respir Crit Care Med, 191, A3441

Metadata

Authors
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R.
Affiliations
  • Clinical Development
  • The Alfred Hospital (AU)
  • Vanderbilt University (US)
  • Tampa General Hospital (US)
  • Clinical Biostatistics and Data Management
  • Clinical Operations, and
  • Translational Medicine, MedImmune, Gaithersburg, Maryland
  • Product Development, MedImmune, Cambridge, United Kingdom; and
  • University of Michigan (US)
Corresponding author
Roseti, Stephanie L.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2018-01-01
Volume
197
Issue
1
Pages
94-103
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2744147503
Cited by
129
References
23
Citations by year
2026: 9 · 2025: 10 · 2024: 13 · 2023: 11 · 2022: 13 · 2021: 23 · 2020: 14 · 2019: 14 · 2018: 16
FWCI
11.07
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
tralokinumab, idiopathic pulmonary fibrosis, IL-13, anti-IL-13 monoclonal antibody, forced vital capacity decline, periostin, treatment efficacy, drug safety and tolerability
MeSH terms
Aged, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Humans, Middle Aged, Prognosis, Severity of Illness Index, Biomarkers, Cell Adhesion Molecules, Survival Rate, Treatment Outcome, Risk Assessment, Maximum Tolerated Dose, Idiopathic Pulmonary Fibrosis, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201704-0784oc
The paper
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018). A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201704-0784oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.